Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of AD-214 in Healthy Volunteers
NCT04415671Phase 1Completed
- Sponsor
- AdAlta
- Start
- Jun 2020
- Primary completion
- Oct 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AD-214 in interstitial lung disease (ILD) (4 arms), sponsored by AdAlta. Primary endpoint: Safety and Tolerability at 57 days. Started Jun 2020; status: completed.
02
Drugs
AD-214
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT04415671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04415671.